CN1444929A - Fibrauretine dispersant tablet and its preparing method - Google Patents
Fibrauretine dispersant tablet and its preparing method Download PDFInfo
- Publication number
- CN1444929A CN1444929A CN 03117415 CN03117415A CN1444929A CN 1444929 A CN1444929 A CN 1444929A CN 03117415 CN03117415 CN 03117415 CN 03117415 A CN03117415 A CN 03117415A CN 1444929 A CN1444929 A CN 1444929A
- Authority
- CN
- China
- Prior art keywords
- fibrauretin
- dispersible tablet
- magnesium stearate
- silica gel
- crospolyvinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
A huangtensu table is prepared from huangtensu, lactose, microcrytical cellulose, cross-linked carboxymethyl cellulose sodium and cross-linked polyvinyl pyrrolidone through mixing, dropping the solution of polyvinyl pyrolidone in alcohol, granulating, drying at 50-80 deg.C, sieving by 18-24 meshes, adding magnesium stearate and powdered silica gel, and tabletting. Its advantages are high disintegration speed in water, dispersity and solubility, and easy absorption.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that contains fibrauretin.More particularly, the present invention relates to a kind of fibrauretin dispersible tablet.The invention still further relates to the preparation method of described fibrauretin dispersible tablet.
Background technology
Caulis Fibraureae (Fibraurea tinctoria Lour) is a kind of subtropical zone wild plant, abounds with in areas such as China Nannings.Compendium of Materia Medica carries: " Caulis Fibraureae gives birth to the south of the Five Ridges, and if shape is Radix Stephaniae Tetrandrae ... abnormal smells from the patient sweetness and bitterness is flat nontoxic, cures mainly the food poisoning, and diuresis, liquor are taken in small doses at short intervals and promptly separate.Yellow with its rattan juice so name." Pharmacopoeia of the People's Republic of China one one of version in 1977 recorded the conventional tablet and the fibrauretin injection of fibrauretin.Obviously, for patient, the oral formulations cost is low, taking convenience.But existing fibrauretin tablet exists also that bioavailability is low, onset waits deficiency slowly, and therapeutic effect is restricted.To this, be necessary to do further research and improve.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, overcome the limitation of existing fibrauretin tablet, provide a kind of absorb fast, bioavailability is high, take and fibrauretin dispersible tablet easy to carry.Simultaneously, the present invention also provides the preparation method of described fibrauretin dispersible tablet.
Purpose of the present invention is achieved by following technical proposals.
Except as otherwise noted, the percent that is adopted among the present invention is percetage by weight.
Fibrauretin dispersible tablet of the present invention, every contains fibrauretin 50mg～500mg and pharmaceutic adjuvant, and described pharmaceutic adjuvant comprises filler 0～200mg, binding agent 0～100mg, disintegrating agent 10～200mg, lubricant 0.1mg～10mg and fluidizer 0.1mg～10mg.Described filler is selected from a kind of in pregelatinized Starch, lactose, mannitol or the microcrystalline Cellulose or their mixture.Described wetting agent is selected from water or ethanol or their mixture.Binding agent is selected from a kind of in hydroxypropyl emthylcellulose, polyvinylpyrrolidone (PVPK30), the methylcellulose or their mixture.Described disintegrating agent is selected from a kind of in microcrystalline Cellulose, low replacement-hyprolose, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium, tween 80, the sodium lauryl sulphate or their mixture.Described lubricant and fluidizer are selected from a kind of in magnesium stearate, Pulvis Talci, Stepanol MG, sodium lauryl sulphate or the micropowder silica gel or their mixture.
The preferred composition of fibrauretin dispersible tablet of the present invention is:
Every fibrauretin dispersible tablet, comprise fibrauretin 50mg～500mg, lactose 0～100mg, microcrystalline Cellulose 0.1mg～100mg, cross-linking sodium carboxymethyl cellulose 0～100mg, crospolyvinylpyrrolidone 2mg～120mg, micropowder silica gel 0.1～10mg, magnesium stearate 0～10mg, sodium lauryl sulphate 0.1～10mg, 5%PVPK30 ethanol liquid is an amount of.
Preparation method of the present invention comprises the step of following order:
1. take by weighing fibrauretin, lactose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, mix homogeneously;
2. Dropwise 5 % polyvinylpyrrolidone K30 ethanol liquid (be dissolved with sodium lauryl sulphate, concentration of alcohol is 60%～80%) system soft material is crossed 18 orders～24 mesh sieves and is granulated;
3. wet granular carries out drying under 50 ℃～80 ℃ conditions;
4. with 18 orders～24 mesh sieve granulate, add magnesium stearate and micropowder silica gel mixing, tabletting promptly gets required fibrauretin dispersible tablet.
Fibrauretin dispersible tablet of the present invention is compared with existing common fibrauretin tablet, has following beneficial effect.
1. have extremely strong disintegrate and dissolving out capability.Disintegrate and stripping are the speed limit processes that oral formulations absorbs, disintegrate rapidly after fibrauretin dispersible tablet of the present invention is oral, and homodisperse becomes fine particle, has incomparable disintegrate of ordinary tablet and stripping property ability, it is fast to take post-absorption, the bioavailability height.Can not there be parallel relation in the disintegration of tablet and intravital absorption, and the reliable method of understanding the body absorption is exactly the bioavailability mensuration of these goods being carried out live body, but mensuration blood drug level, method such as urine excreion rate and metabolite thereof more complicated, experimental results show that, the external stripping of the tablet of medicine be absorbed with dependency, so dissolution method can reflect or analogue body in absorbing state.
(1) the disintegrate situation of fibrauretin dispersible tablet and fibrauretin sheet relatively.
The mensuration of dispersing uniformity: get 2 fibrauretin dispersible tablets or common fibrauretin sheet, place the jolting of 100ml water respectively, under 20 ℃ ± 1 ℃ temperature, 3 minutes all disintegrate and by No. 2 the sieve.Result of the test sees Table 1.
Table 1.
| Kind | Disintegration |
| The fibrauretin dispersible tablet | 40 seconds |
| The fibrauretin sheet | 270 seconds |
(2) fibrauretin dispersible tablet and fibrauretin sheet stripping situation are relatively
Sample thief, be dissolution medium with 900 milliliters of purified water respectively, 37 ℃ of temperature, rotating speed 120r/min, respectively at 2,4,6,8,10,15,20,30,45,60 minutes 5 milliliters of timing spot samplings (replenishing same medium simultaneously), 45 μ m filtering with microporous membranes are measured stripping quantity, calculate accumulation stripping percentage rate relatively.Result of the test sees Table 2.
Table 2.
| Time (minute) | ????2 | ????4 | ????6 | ????8 | ????10 | ????15 | ????20 | ????30 | ????45 | ????60 |
| Dispersible tablet | ??85.69 | ??87.36 | ??89.23 | ??90.32 | ??91.36 | ??93.69 | ??95.26 | ??95.36 | ??95.36 | ??95.40 |
| Ordinary tablet | ??31.71 | ??55.36 | ??64.42 | ??70.25 | ??72.35 | ??73.64 | ??74.40 | ??75.23 | ??75.31 | ??75.32 |
Result of the test shows that the dissolution rate of dispersible tablet obviously is better than ordinary tablet.
2. fibrauretin dispersible tablet of the present invention is can the rapid uniform tablet of disintegrate in water.Collapse agent and good mixed with excipients pelletizing press sheet forms stable quality after long time storage by medicine and specific speed.Disintegrate and stripping are the speed limit processes that oral formulations absorbs, and rapid disintegrate of energy and homodisperse became fine particle after dispersible tablet was oral, had incomparable disintegrate of ordinary tablet and stripping property ability, and it is fast to take post-absorption, the bioavailability height.Dispersible tablet can add after the aqueous dispersion oral, also it can be contained in and suck clothes in the mouth, take carry very convenient.
3. fibrauretin dispersible tablet of the present invention is that the dosage form of carrying out on the basis of former conventional tablet is improved, and the fibrauretin dispersible tablet has broad-spectrum antiseptic, antiviral, and antiinflammatory has the leukocyte of enhancing and gulps down ability.Be used for the treatment of the various inflammation of gynecological such as puerperal infection, acute and chronic vaginitis, urgent chronic pelvic inflammatory disease, chronic cervicitis, colpitis mycotica, vulvitis; Respiratory tract infection such as acute and chronic tonsillitis, acute/chronic bronchitis; Acute/chronic gastroenteritis, toxic indigestion; Surgical infection; Urinary tract infection; Diseases such as eye conjunctivitis.
By nearly outside the province 50 tame large hospitals such as First People's Hospital, Yunnan, first, second Affiliated Hospital of unming Medical College and Yunnan Province institute of traditional Chinese medicine and Beijing, Shanghai, the clinical observation statistical data analysis is as follows:
(1) patient profile: select projects such as relevant medical history, the state of an illness, age, sex.
(2) patient source: with general hospital out-patient and specialist hospital inpatient.
(3) method of administration, a 0.2g～0.4g, 0.6g～1.2g on the one.
(4) disease type and curative effect see Table 3
Table 3
Continuous table
| Disease name | The example number | Recovery from illness | Produce effects | Invalid | |||
| The example number | ????％ | The example number | ????％ | The example number | ????％ | ||
| The acute and chronic adnexitis | ????219 | ????130 | ????59.3 | ????72 | ????32.8 | ????17 | ????7.7 |
| Urgent chronic pelvic inflammatory disease | ????95 | ????44 | ????46.3 | ????44 | ????46.3 | ????7 | ????7.4 |
| The acute and chronic cervicitis | ????184 | ????78 | ????42.4 | ????87 | ????47.6 | ????19 | ????10 |
| Acute and chronic palace intimitis | ????30 | ????19 | ????63.3 | ????8 | ????26.6 | ????3 | ????10 |
| Vulvitis | ????8 | ????1 | ????12.5 | ????7 | ????87.5 | ????0 | |
| The acute and chronic vaginitis | ????13 | ????12 | ????92.31 | ????1 | ????7.69 | ????0 | |
| Colpitis mycotica | ????12 | ????6 | ????50.0 | ????6 | ????50.0 | ????0 | |
| Puerperal infection | ????10 | ????10 | ????100 | ????0 | ????0 | ||
| Other gynecological inflammation | ????43 | ????43 | ????100 | ????0 | ????0 | ||
| Urinary tract infection | ????61 | ????38 | ????62.2 | ????19 | ????31.1 | ????4 | ????6.5 |
| Orchitis | ????6 | ????5 | ????83.3 | ????1 | ????16.7 | ????0 | |
| Fungal infection | ????7 | ????5 | ????71.43 | ????2 | ????28.57 | ????0 | |
| Acute appendicitis | ????14 | ????8 | ????57.14 | ????6 | ????42.86 | ????0 | |
| The acute and chronic bacillary dysentery | ????203 | ????119 | ????58.62 | ????49 | ????24.13 | ????35 | ????17.25 |
| Biliary tract infection | ????12 | ????6 | ????50.00 | ????6 | ????50.00 | ????0 | |
| Upper respiratory tract infection | ????140 | ????130 | ????93.0 | ????10 | ????7 | ????0 | |
| Influenza | ????6 | ????5 | ????83.33 | ????1 | ????16.67 | ????0 | |
| Acute and chronic tracheitis | ????26 | ????19 | ????73.08 | ????6 | ????23.08 | ????1 | ????3.84 |
| Bronchopneumonia | ????54 | ????44 | ????81.4 | ????3 | ????5.6 | ????7 | ????13 |
| The acute and chronic tonsillitis | ????86 | ????79 | ????92.0 | ????7 | ????8 | ????0 | |
| Oral cavity, faciomaxillary region inflammation | ????23 | ????19 | ????82.9 | ????4 | ????17.1 | ????0 | |
| Otitis media | ????8 | ????4 | ????50.0 | ????2 | ????25.0 | ????2 | ????25.0 |
| Eczema | ????9 | ????8 | ????88.89 | ????1 | ????11.11 | ????0 | |
| Surgery and trauma infection contamination | ????82 | ????77 | ????93.9 | ????5 | ????6.1 | ????0 | |
| Acute/chronic gastroenteritis | ????53 | ????51 | ????98.1 | ????2 | ????1.9 | ????0 | |
| Toxic indigestion | ????24 | ????18 | ????75.0 | ????6 | ????25.0 | ????0 | |
| Infantile dyspepsia | ????20 | ????20 | ????100 | ????0 | ????0 | ||
| The furuncle carbuncle | ????43 | ????39 | ????90.7 | ????4 | ????9.3 | ????0 |
Description of drawings
Fig. 1 is the external stripping curve of fibrauretin dispersible tablet of the present invention and common fibrauretin sheet.
Among the figure:---fibrauretin dispersible tablet stripping curve;
---common fibrauretin sheet stripping curve.
The result shows among the figure, fibrauretin dispersible tablet drug accumulation stripping percentage rate is high by 85% in the time of 2 minutes, surpassed 95% in the time of 20 minutes, and common fibrauretin sheet is accumulated the stripping percentage rate and is only reached 75% in the time of 60 minutes, this shows that the dissolution rate of dispersible tablet obviously is better than ordinary tablet.
The specific embodiment
By specific embodiment given below, can further be well understood to the present invention.But they are not limitation of the invention.
Embodiment 1
Take by weighing fibrauretin 50mg, lactose 30mg, microcrystalline Cellulose 20mg, cross-linking sodium carboxymethyl cellulose 10mg, crospolyvinylpyrrolidone 20mg, sodium lauryl sulphate 1.2mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.2mg and micropowder silica gel 1mg mixing, tabletting is made product.
Embodiment 2
Take by weighing fibrauretin 50mg, lactose 25mg, mannitol 10mg, microcrystalline Cellulose mg, crospolyvinylpyrrolidone 30mg, sodium lauryl sulphate 1.2mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.2mg and micropowder silica gel 1mg mixing, tabletting is made product.
Embodiment 3
Take by weighing fibrauretin 50mg, pregelatinized Starch 20mg, microcrystalline Cellulose 40mg, crospolyvinylpyrrolidone 20mg, mix homogeneously; Dropwise 5 %PKPV30 ethanol liquid system (being added with tween 80) system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.2mg mixing, tabletting is made product.
Embodiment 4
Take by weighing fibrauretin 100mg, lactose 10mg, microcrystalline Cellulose 10mg, crospolyvinylpyrrolidone 20mg, mix homogeneously; Dropwise 5 % hydroxypropyl methylcellulose ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.2mg and carboxymethyl starch sodium 3mg mixing, tabletting is made product.
Embodiment 5
Take by weighing fibrauretin 100mg, lactose 5mg, microcrystalline Cellulose 10mg, cross-linking sodium carboxymethyl cellulose 20mg, Stepanol MG 1.2mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add Pulvis Talci 1.5mg and micropowder silica gel 1mg mixing, tabletting is made product.
Embodiment 6
Take by weighing fibrauretin 100mg, mannitol 20mg, crospolyvinylpyrrolidone 25mg, sodium lauryl sulphate 1.2mg, mix homogeneously; Dropwise 5 %PVPK ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1mg and micropowder silica gel 1mg mixing, tabletting makes product.
Embodiment 7
Take by weighing fibrauretin 100mg, pregelatinized Starch 5mg, low replacement-hyprolose 10mg, crospolyvinylpyrrolidone 20mg, sodium lauryl sulphate 1.2mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.2mg and micropowder silica gel 1mg mixing, tabletting makes product.
Embodiment 8
Take by weighing fibrauretin 100mg, microcrystalline Cellulose 10mg, crospolyvinylpyrrolidone 25mg, mix homogeneously; 10% hypromellose alcoholic solution (being added with tween 80) is made soft material in right amount, crosses 18～30 mesh sieves and granulates, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.2mg and micropowder silica gel 1.0mg mixing, tabletting makes product.
Embodiment 9
Take by weighing fibrauretin 100mg, microcrystalline Cellulose 10mg, crospolyvinylpyrrolidone 20mg, sodium lauryl sulphate 1.2mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.2mg and carboxymethyl starch sodium 2mg mixing, tabletting makes product.
Embodiment 10
Take by weighing fibrauretin 150mg, lactose 10mg, crospolyvinylpyrrolidone 40mg, sodium lauryl sulphate 1.2mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 2mg and micropowder silica gel 1.5mg mixing, tabletting makes product.
Embodiment 11
Take by weighing fibrauretin 150mg, pregelatinized Starch 10mg, low replacement-hyprolose 20mg, crospolyvinylpyrrolidone 20mg, mix homogeneously; 10% hypromellose alcoholic solution is made soft material in right amount, crosses 18～30 mesh sieves and granulates, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 2.0mg and micropowder silica gel 1.5mg mixing, tabletting makes product.
Embodiment 12
Take by weighing fibrauretin 150mg, microcrystalline Cellulose 10mg, cross-linking sodium carboxymethyl cellulose 20mg, crospolyvinylpyrrolidone 20mg, mix homogeneously; 10% hypromellose alcoholic solution is made soft material in right amount, crosses 18～30 mesh sieves and granulates, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 1.5mg and micropowder silica gel 1.5mg mixing, tabletting makes product.
Embodiment 13
Take by weighing fibrauretin 200mg, pregelatinized Starch 10mg, cross-linking sodium carboxymethyl cellulose 50mg, mix homogeneously; 10% hypromellose alcoholic solution (being added with tween 80) is made soft material in right amount, crosses 18～30 mesh sieves and granulates, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 2.0mg and micropowder silica gel 1.5mg mixing, tabletting makes product.
Embodiment 14
Take by weighing fibrauretin 200mg, microcrystalline Cellulose 15mg, cross-linking sodium carboxymethyl cellulose 45mg, sodium lauryl sulphate 2.0mg, mix homogeneously; 5%PVPK30 alcoholic solution system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 2.0mg and micropowder silica gel 1.5mg mixing, tabletting makes product.
Embodiment 15
Take by weighing fibrauretin 200mg, microcrystalline Cellulose 10mg, crospolyvinylpyrrolidone 40mg, low replacement-hyprolose 10mg, sodium lauryl sulphate 2mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 3.5mg and micropowder silica gel 2mg mixing, tabletting makes product.
Embodiment 16
Take by weighing fibrauretin 300mg, lactose 10mg, crospolyvinylpyrrolidone 70mg, sodium lauryl sulphate 4mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 3.5mg and micropowder silica gel 2mg mixing, tabletting makes product.
Embodiment 17
Take by weighing fibrauretin 300mg, mannitol 10mg, crospolyvinylpyrrolidone 70mg, Stepanol MG 4mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50～80 ℃ of conditions.With 18～30 mesh sieve granulate, add magnesium stearate 3.5mg and micropowder silica gel 2mg mixing, tabletting makes product.
Embodiment 18
Take by weighing fibrauretin 300mg, lactose 10mg, microcrystalline Cellulose 5mg, cross-linking sodium carboxymethyl cellulose 60mg, sodium lauryl sulphate 4mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 3.5mg and carboxymethyl starch sodium 4mg mixing, tabletting makes product.
Embodiment 19
Take by weighing fibrauretin 400mg, microcrystalline Cellulose 10mg, crospolyvinylpyrrolidone 80mg, sodium lauryl sulphate 5mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50～80 ℃ of conditions.With 18～30 mesh sieve granulate, add magnesium stearate 4.5mg and micropowder silica gel 2mg mixing, tabletting makes product.
Embodiment 20
Take by weighing fibrauretin 400mg, microcrystalline Cellulose 6mg, crospolyvinylpyrrolidone 80mg, sodium lauryl sulphate 5mg, mix homogeneously; Dropwise 5 %PVPK30 ethanol liquid system soft material is crossed 18～30 mesh sieves and is granulated, and wet granular carries out drying under 50 ℃～80 ℃ conditions.With 18～30 mesh sieve granulate, add magnesium stearate 4.5mg and carboxymethyl starch sodium 5mg mixing, tabletting makes product.
Claims (4)
1. fibrauretin dispersible tablet, every contains fibrauretin 50mg～500mg and pharmaceutic adjuvant, and described pharmaceutic adjuvant comprises filler 0～200mg, binding agent 0～100mg, disintegrating agent 10～200mg, lubricant 0.1mg～10mg and fluidizer 0.1mg～10mg.
2. according to the described fibrauretin dispersible tablet of claim 1, wherein said filler is selected from a kind of in pregelatinized Starch, lactose, mannitol or the microcrystalline Cellulose or their mixture; Described wetting agent is selected from water or ethanol or their mixture; Described binding agent is selected from a kind of in hydroxypropyl emthylcellulose, polyvinylpyrrolidone, the methylcellulose or their mixture; Described disintegrating agent is selected from a kind of in microcrystalline Cellulose, low replacement-hyprolose, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, carboxymethyl starch sodium, tween 80, the sodium lauryl sulphate or their mixture; Described lubricant and fluidizer are selected from a kind of in magnesium stearate, Pulvis Talci, Stepanol MG, sodium lauryl sulphate or the micropowder silica gel or their mixture.
3. fibrauretin dispersible tablet according to claim 2, every comprises fibrauretin 50mg～500mg, lactose 0～100mg, microcrystalline Cellulose 0.1mg～100mg, cross-linking sodium carboxymethyl cellulose 0～100mg, crospolyvinylpyrrolidone 2mg～120mg, micropowder silica gel 0.1～10mg, magnesium stearate 0～10mg, sodium lauryl sulphate 0.1～10mg, 5%PVPK30 ethanol liquid is an amount of.
4. the preparation method of a fibrauretin dispersible tablet, this method comprises the step of following order:
(1) takes by weighing fibrauretin, lactose, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, mix homogeneously;
(2) Dropwise 5 % polyvinylpyrrolidone K30 ethanol liquid system soft material is crossed 18 orders～24 mesh sieves and is granulated;
(3) wet granular carries out drying under 50 ℃～80 ℃ conditions;
(4) with 18 orders～24 mesh sieve granulate, add magnesium stearate and micropowder silica gel mixing, tabletting promptly gets required fibrauretin dispersible tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117415 CN1230156C (en) | 2003-03-07 | 2003-03-07 | Fibrauretine dispersant tablet and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117415 CN1230156C (en) | 2003-03-07 | 2003-03-07 | Fibrauretine dispersant tablet and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1444929A true CN1444929A (en) | 2003-10-01 |
| CN1230156C CN1230156C (en) | 2005-12-07 |
Family
ID=27814946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03117415 Expired - Lifetime CN1230156C (en) | 2003-03-07 | 2003-03-07 | Fibrauretine dispersant tablet and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1230156C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626397A (en) * | 2012-04-25 | 2012-08-08 | 云南植物药业有限公司 | Hydrophilic gel type palmatine sustained-release tablet and preparation method thereof |
-
2003
- 2003-03-07 CN CN 03117415 patent/CN1230156C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102626397A (en) * | 2012-04-25 | 2012-08-08 | 云南植物药业有限公司 | Hydrophilic gel type palmatine sustained-release tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1230156C (en) | 2005-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1131027C (en) | Controlled release formulation for poorly soluble basic drugs | |
| CN1562024A (en) | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease | |
| CN1813686A (en) | Montelukast oral disintegrating tablet formulation and its preparing method | |
| CN101019876B (en) | Compound roxithromycin dispersing tablet | |
| CN1709245A (en) | Use of levo-ornidazole for preparing anti-parasitic-infectious drug | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN1943586A (en) | Oral disintegrating tablet using roxithromycin and ambroxol hydrochloride as active component and its preparing method and use | |
| CN1230156C (en) | Fibrauretine dispersant tablet and its preparing method | |
| WO2005039561A1 (en) | Micronized bicyclol and the orally administered controlled release formulation | |
| CN1864679A (en) | A composite bergenin dispersible tablet and preparation method thereof | |
| CN1817346A (en) | Benzoyl metronidazole dispersion tablets and preparation thereof | |
| CN1586483A (en) | Oral disintegration tablet of silaenafil and its pharmaceutically receptible salt and its preparing method | |
| CN101084904A (en) | Cefixime sustained-release double-layer tablet | |
| CN1241568C (en) | Compound paracetamol and chlorphenamine maleate slow releasing tablet and its preparation | |
| CN1823808A (en) | Clindamycin palmitate hydrochloride dispersion tablet and its preparation method | |
| CN1546046A (en) | Adefovir dipivoxil dispersing tablet and its preparation | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| CN1672680A (en) | Stable moxixacin tablet and its prepn process | |
| CN1586470A (en) | Silibinin oral disintegration tablet and its preparing method | |
| CN1247203C (en) | Helicidum oral disintegation tablet and its preparing method | |
| CN1742726A (en) | Piperazine ferulate oral cavity disintegrating tablet and preparing method | |
| CN1589782A (en) | Dimethyl biguanidine hydrochloride slow release particle and its preparation method | |
| CN1927372A (en) | Antiviral dispersant tablet and method for making same | |
| CN1872160A (en) | Sloly released tablet of red sage root, and preparation method | |
| CN1692909A (en) | Dosmalfate dispersion tablet and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20051207 |
|
| CX01 | Expiry of patent term |